You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Using MammaPrint to guide breast cancer chemo de-escalation could result in significant healthcare savings in five of six evaluated countries, according to the analysis.
At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.
MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.
Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.
ASCO said MammaPrint should be used to inform decisions on withholding chemotherapy for these clinically high risk, HR-positive, HER2-negative breast cancers.